- Hims & Hers says it plans to sell compounded peptides, touting U.S.-made products, clinical-led guidance and ongoing blood testing while validating ingredient supply chains if the FDA allows compounding.
- Injectable peptides have gotten hot recently, helped along by public enthusiasm from HHS Secretary Robert F. Kennedy.
- An FDA advisory committee narrowly voted to let certain peptides (BPC-157, KPV, TB-500, MOTS-c) be added to compounding lists despite agency scientists raising doubts about proven benefits.
The news, distilled into what matters.
Get the full experience in the app — topics, comments, and audio summaries.